HIV.gov hosted a discussion on the findings of the PURPOSE 1 study where the safety and efficacy of lenacapavir as long-acting injectable PrEP among cisgender women. Brian Minalga facilitated the talk with Dr. Carl Dieffenbach from NIAID, Tori Cooper from HRC, and Dr. Jono Mermin from CDC..
